The France blister packaging market is projected to witness a compound annual growth rate of 2.47% to grow to US$437.804 million by 2028, from US$369.065 million in 2021.
One of the main causes of the gradual adoption of blister packaging in the pharmaceutical industry has been the prevalence of fake medications in the nation. Further, the demand for prescription and over-the-counter medications is expected to increase steadily as more French people spend money on their healthcare requirements.
The rising trend of short-cycle medicine, greater patient adherence, rising off-patenting of medications, and unit-dosing regulations are driving factors in the France blister packaging industry. All of these elements are anticipated to increase blister packaging demand in France in the pharmaceutical packaging business.
According to OEC data, France became the sixth-largest importer of special pharmaceuticals in the world in 2021, bringing in $556M. Special Pharmaceuticals was France's 259th most-imported product in 2021. Special pharmaceuticals are mostly imported by France from Germany ($112M), Belgium ($86.6M), the Netherlands ($57.4M), Italy ($55.2M), and Ireland ($47.8M). Between 2020 and 2021, Belgium ($25.2M), Germany ($18.8M), and Austria ($5.85M) had the fastest-growing import markets for Special Pharmaceuticals for France. The growth is anticipated to significantly impact the blister packaging market in France.
Benefits of Blister Packaging
Blister packaging's main objective is to preserve the integrity of the product, although efforts are still being made in all facets of the packaging business to save costs throughout the packaging process. To assure the optimum protection for pharmaceutical applications like tablets and capsules, Amcor's Polybar barrier film product families offer a wide range of moisture barriers in addition to having strong crush resistance. It uses various materials including Aclar, COC, PE, PVC, and PVDC.
The market for blister packaging in France is expanding because of emerging trends including senior-friendly features, RFID-enabled medication compliance, pressure-sensitive push-through blisters (AOF), and CR packaging with an anti-lock mechanism.
Growing Healthcare Expenditure and Product Development
Pharmaceutical businesses have started using outsourcing as a result of growing healthcare costs and a broadening demand for pharmaceutical products worldwide. To produce pharmaceuticals on a wider scale, contract development manufacturing Active pharmaceutical ingredients (API), medicinal product development, and packaging services are all offered by contract development and manufacturing companies.
As French people are becoming more health aware, manufacturers are focusing on product innovation and development, which is significantly fueling the healthcare expenditure in the nation. For instance, according to World Bank Data, France's healthcare expenditure increased from 11.09% of the GDP in 2019 to 12.02% in 2020. The surge in healthcare expenditure fuels the use of blister packaging in the region.
The use of blister packaging in Pharmaceuticals
Blister packaging is a pre-formed plastic packaging that uses thermoplastic such as polyvinyl chloride (PVC) or polyethylene terephthalate (PET) as packaging material. The ability of such packaging types to preserve product integrity has enabled it to find major usage in pharmaceutical packaging. Growing chronic disease prevalence has propelled the medicine demand in France thereby increasing the overall healthcare expenditure which is expected to positively impact the blister packaging usage in France’s pharmaceutical sector. For instance, according to the LEEM (France Pharmaceutical Industry Association), France’s retail pharmacy sales in 2020 reached €21.2 billion which represented a 1.9% increase over 2019.
According to the European Federation of Pharmaceutical Industries and Association, in 2021, Pharmaceutical production in France reached €23,557 million and as per the same source, the research and development in the country’s pharmaceuticals sector stood at €4,451 million. Also, as per the Eurostat data, healthcare expenditure accounted for 12.4% of the total France’s GDP in 2021 which signified a 10.7% increase over 2010’s healthcare spending.
Besides the pharmaceutical sector’s steady growth, the well-established presence of market players such as Laboratoire Diephez which provides more than 150 blister pack formats for pharmaceutical packaging in France and produces over 50 million blister packs a year is acting as an additional driving factor for France blister packaging market growth.
Key Developments
| Report Metric | Details |
|---|---|
| Study Period | 2021 to 2031 |
| Historical Data | 2021 to 2024 |
| Base Year | 2025 |
| Forecast Period | 2026 – 2031 |
| Report Metric | Details |
| Market Size Value in 2021 | US$369.065 million |
| Market Size Value in 2028 | US$437.804 million |
| Growth Rate | CAGR of 2.47% from 2021 to 2028 |
| Base Year | 2021 |
| Forecast Period | 2023 – 2028 |
| Forecast Unit (Value) | USD Million |
| Segments Covered | Type, Material, Technology, and End-User |
| Companies Covered | Novartis France, Nelipak, Uhlmann Group, Sonoco Products Company, WestRock, Strobel GmbH, Constantia Flexibles, Schreiner Group, Laboratoire Diephez |
| Customization Scope | Free report customization with purchase |
Segmentation: